(NASDAQ: KYTX) Kyverna Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 251.16%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 12.95%.
Kyverna Therapeutics's revenue in 2024 is $0.On average, 1 Wall Street analysts forecast KYTX's revenue for 2024 to be $646,728,660, with the lowest KYTX revenue forecast at $646,728,660, and the highest KYTX revenue forecast at $646,728,660. On average, 1 Wall Street analysts forecast KYTX's revenue for 2025 to be $862,304,880, with the lowest KYTX revenue forecast at $862,304,880, and the highest KYTX revenue forecast at $862,304,880.
In 2029, KYTX is forecast to generate $1,862,578,541 in revenue, with the lowest revenue forecast at $1,862,578,541 and the highest revenue forecast at $1,862,578,541.